Enliven Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $18,225 | $21,258 | $64,611 | $60,054 |
| General and administrative | 6,871 | 5,810 | 20,762 | 17,604 |
| Total operating expenses | 25,096 | 27,068 | 85,373 | 77,658 |
| Loss from operations | (25,096) | (27,068) | (85,373) | (77,658) |
| Other income (expense), net | ||||
| Interest income | 4,948 | 3,839 | 11,395 | 11,175 |
| Change in fair value of contingent value right liability | — | 73 | — | 873 |
| Income tax expense | — | — | — | (232) |
| Other expense | — | — | (49) | (2) |
| Total other income (expense), net | 4,948 | 3,912 | 11,346 | 11,814 |
| Net loss | (20,148) | (23,156) | (74,027) | (65,844) |
| Other comprehensive income (loss): | ||||
| Net unrealized gains on marketable securities | 398 | 381 | 166 | 101 |
| Comprehensive loss | $(19,750) | $(22,775) | $(73,861) | $(65,743) |
| Net loss per share, basic and diluted | $(0.32) | $(0.48) | $(1.35) | $(1.43) |
| Weighted-average shares outstanding, basic and diluted | 62,093,795 | 48,267,458 | 54,794,155 | 46,137,170 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.